# Ro account plan

> Ro is a private US telehealth company, mostly GLP-1 weight-loss programmes, with more than $3 billion in annualized revenue.

## At a glance

Ro is a privately held, venture-backed US telehealth company, founded as Roman in 2017, that sells GLP-1 treatments such as Wegovy and Zepbound through its Ro Body subscription service, alongside other treatments. It announced more than $3 billion in annualized revenue in November 2026, up nearly tenfold since the 2022 revamp, with a team of roughly 400 according to its CEO on a podcast. It has not raised new money from investors in years and says it can fund itself from operations. Zachariah Reitano is co-founder and CEO.

## Strategic priorities

- **Branded GLP-1 leadership**: Reitano says Ro always worked directly with Novo Nordisk and Eli Lilly and is now the largest provider of branded GLP-1 drugs in the United States. He says Ro integrates with both companies.
- **Protecting margins on branded drugs**: Selling branded drugs has taken a toll on telehealth margins. Reitano argues Ro expects higher margins because of subscriptions and cost efficiency, and says it cut the cost of its membership plans.
- **AI in patient care and support**: Reitano says AI will speed up customer service queries and personalise treatment; he also says AI was used to help more than 1% of the US population check their insurance for free.
- **Celebrity-led campaigns to reduce stigma**: Ro features ambassadors including Serena Williams and Charles Barkley, and Reitano says every ambassador actually uses the product.
- **Patient-funded care**: Reitano's thesis is that where patients pay directly, prices fall and volume rises; he predicts more than half of Americans on some form of GLP-1 within 10-15 years.

## Latest results

In November 2026 Ro announced more than $3 billion in annualized revenue, up nearly tenfold since the company revamped its business starting in 2022. On the podcast, Reitano put the move at about a $250 million to a $3 billion run rate, with headcount down from more than 600 to roughly 400. These are figures stated by the company and its CEO; no audited accounts were read.

## Investments and deals

- **Own infrastructure**: Ro spent four to five years building its own electronic medical records system, its own CLIA-certified lab, its own pharmacy software and its own provider network.
- **Ro Body (2023)**: Subscription service launched in 2023 to help customers obtain GLP-1 treatments and navigate insurance.
- **Marketing**: Digital ads, TV commercials, subway posters and influencer campaigns, plus a Super Bowl ad with Serena Williams in 2026.
- **Funding history**: A $500 million raise at a $5 billion valuation in spring 2021; Ro has raised around $1 billion to date according to PitchBook.

## Challenges and risks

- **Margin pressure from branded drugs**: Selling branded drugs has taken a toll on telehealth companies' margins; Hims lowered its earnings guidance for the year.
- **Drug makers' own direct-to-consumer sales**: Novo Nordisk and Eli Lilly are building their own direct-to-consumer businesses while also working with Ro.
- **Supply shortages**: In 2024 shortages led Ro to pause advertising temporarily and to make 50,000 phone calls to pharmacies between July and August to transfer prescriptions.
- **Public reaction to its marketing**: The Serena Williams Super Bowl ad ranked near the bottom of a USA Today survey of Super Bowl ads, though Reitano says it helped persuade more consumers to seek treatment.

## What leadership says

> "We were just really a zombie company." — Zachariah Reitano, Co-Founder & CEO, Interview in a news article syndicated 2026-11-12

> "sometimes the best time to raise money is when you don't need it." — Zachariah Reitano, Co-Founder & CEO, Interview in a news article syndicated 2026-11-12, on a possible public listing


## Where a supplier can help

- **Pharmacy and fulfilment services**: Tied to supply shortages and the 50,000 pharmacy calls made to transfer prescriptions: pharmacy-network and logistics suppliers.
- **AI customer-support and insurance tooling**: Tied to the priority on AI for customer service and personalisation: vendors of patient messaging and insurance-verification software.
- **Marketing and creative production**: Tied to the celebrity-led campaigns and digital, TV and subway advertising: creative, media and measurement partners.
- **Margin and cost-efficiency programmes**: Tied to margin pressure from branded drugs: suppliers that lower cost per patient served.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [How GLP-1 Drugs and a Revamp Revived Ro's Business (news article with CEO interview, syndicated copy)](https://www.newsbeep.com/au/962059/)

Executive talk · Zachariah Reitano, Co-Founder and CEO · 2026-11-12

- Ro announced it had more than $3 billion in annualized revenue, up nearly tenfold since the company revamped its business starting in 2022.
- Ro is nine years old and privately held; it has not raised new money from investors in years, and Reitano says it can fund itself from operations and could be profitable if it chose to be.
- Before the revamp, growth plateaued at 9 percent year-on-year after a $500 million raise at a $5 billion valuation in spring 2021; Reitano: "We were just really a zombie company."
- The "re-founding" shut more than 10 product lines, dropped long-term road maps, and cut about 20 percent of the work force by June 2022.
- In 2023 Ro launched the Ro Body subscription service for GLP-1 treatments such as Wegovy and Zepbound.
- Reitano says Ro always worked directly with Novo Nordisk and Eli Lilly and is now the largest provider of branded GLP-1 drugs in the United States.
- Selling branded drugs has hurt telehealth margins (Hims lowered its guidance); Reitano expects Ro to keep higher margins thanks to subscriptions and cost efficiency.
- A Serena Williams Super Bowl ad this year drew attention and criticism; Reitano says it helped persuade more consumers to seek GLP-1 treatments.

### [Invest Like the Best with Zach Reitano: The Patient Revolution (written account of the episode, BigGo Finance)](https://finance.biggo.com/news/ebfe80be2f4a9cec)

Podcast · Zachariah Reitano, Co-Founder and CEO

- Reitano argues the core flaw of US healthcare is that the patient is not the customer at the point of purchase; GLP-1s sold direct to consumers are his proof it can be fixed.
- He says cash-pay competition cut GLP-1 prices from roughly $1,300 to $149 per month while drugmakers made more money on volume.
- He predicts more than half of Americans will be on some form of GLP-1 within 10-15 years, versus roughly 10-15% today.
- Turnaround: after raising $500 million at a $5 billion valuation in January 2021 and growing 9% that year, Ro cut about seven VPs and 20% of staff and refounded under one brand.
- He cites revenue up from about a $250 million to a $3 billion run rate and headcount down from more than 600 to roughly 400, with roughly 100% year-over-year growth for four years.
- He says Ro built its own EMR, CLIA-certified lab, pharmacy software and provider network; it works with both Novo Nordisk and Eli Lilly.
- He defends celebrity campaigns (Serena Williams, Charles Barkley) as a way to reduce stigma around treatment.

### [Digital health companies are launching programs around GLP-1s (CNBC)](https://www.cnbc.com/2024/05/25/digital-health-companies-are-launching-programs-around-glp-1s-.html)

Report · 2024-05-25

- CNBC profiles Ro among digital health companies building GLP-1 programs; Ro was founded as Roman in 2017 and started with erectile dysfunction treatments.
- In 2020 Ro switched to obesity management; after Wegovy's FDA approval the following year, Reitano said patient inquiries came in by the "tens of thousands".
- The Ro Body Program offers a prescribed GLP-1, monthly doctor meetings, an educational curriculum, 24/7 messaging, nurse coaching and insurance help, for a $145 monthly fee.
- Ro has raised around $1 billion to date according to PitchBook, and was valued at about $7 billion as of early 2022.
- Reitano described GLP-1s as a "jetpack for positive behavior change" and said patients see around a 30% reduction in calorie intake.
- During shortages Ro paused advertising, refunded patients, and made 50,000 phone calls to pharmacies from July to August to transfer prescriptions; it added Zepbound after approval in November.

## Questions about Ro

### What does Ro do?

Ro is a US telehealth company whose main business is GLP-1 weight-loss treatments such as Wegovy and Zepbound, sold through its Ro Body subscription service.

### How large is Ro?

In November 2026 Ro announced more than $3 billion in annualized revenue, up nearly tenfold since 2022.

### Is Ro publicly listed?

No. Ro is privately held and has not raised new money from investors in years; the CEO would not commit to a public listing.

### Who leads Ro?

Zachariah Reitano is co-founder and CEO.

### How many people work at Ro?

On the podcast Reitano said the team is roughly 400, down from more than 600.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)_
